<DOC>
<DOCNO>EP-0648779</DOCNO> 
<TEXT>
<INVENTION-TITLE>
New 11-benzaldehyde oxime, 17-beta methoxy, 17 alpha methoxymethyl derivates of estradiene, a process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07J7500	A61P3500	C07J4100	A61P1300	A61P1500	A61K31565	A61K3156	C07J100	C07J100	A61P1302	C07J7500	A61K31565	A61P1500	A61K3156	A61P3500	C07J4100	A61P500	A61P524	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07J	A61P	C07J	A61P	A61P	A61K	A61K	C07J	C07J	A61P	C07J	A61K	A61P	A61K	A61P	C07J	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07J75	A61P35	C07J41	A61P13	A61P15	A61K31	A61K31	C07J1	C07J1	A61P13	C07J75	A61K31	A61P15	A61K31	A61P35	C07J41	A61P5	A61P5	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
11-Benzaldoxime-oestradiene derivatives of the general formula I 
<
IMAGE
>
 and their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them are described. The described compounds display potent antigestagenic effects with lower glucocorticoid activity.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
JENAPHARM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
JENAPHARM GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ELGER WALTER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KAUFMANN GUENTER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KURISCHKO ANATOLI DR
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL MICHAEL PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUBERT GERD DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SOBECK LOTHAR DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ELGER, WALTER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KAUFMANN, GUENTER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KURISCHKO, ANATOLI, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL, MICHAEL, PROF.DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUBERT, GERD, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SOBECK, LOTHAR, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
11β-benzaldoxime-estra-4,9-diene derivatives of the 
general formula I 


 
where 


Z is -CO-CH
3
, -CO-O-C
2
H
5
, -CO-NH-phenyl, -CO-NH-C
2
H
5
, 
-CO-C
2
H
5
, or CO-phenyl, 
 
as well as their pharmaceutically acceptable salts. 
Compounds according to Claim 1, namely 


11β-[4-(acetoximinomethyl)phenyl]-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on, 
11β-{4-[(ethoxycarbonyl)oximinomethyl]phenyl}-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on, 
11β-{4-[(ethylaminocarbonyl)oximinomethyl]phenyl}-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on,  

 
17β-methoxy-17α-methoxymethyl-11β-{4-[(phenylaminocarbonyl)oximinomethyl]phenyl}-estra-4,9-diene-3-on, 
11β-[4-(propionyloximinomethyl)phenyl]-17β-methoxy-17α 

-methoxymethyl-estra-4,9-diene-3-on, and 
11β-[4-(benzoyloximinomethyl)phenyl]-17β-methoxy-17α-methoxymethyl-estra-4,9-diene-3-on. 
Methods for producing the compounds according to 
claim 1 and their pharmaceutically acceptable salts, 

characterized in that a compound of the general 
formula II 


 
is esterified with the group Z and the resulting 

compound is optionally converted into a 
pharmaceutically acceptable salt. 
Pharmaceutical compositions, characterized in that 
they contain at least one compound according to claims 

1 to 2. 
</CLAIMS>
</TEXT>
</DOC>
